DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and 2,300 generic ingredients from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 4,400 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices.
Summary for Tradename: RECLAST
Clinical Trials for: RECLAST
Perioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer
Status: Active, not recruiting Condition: Adenocarcinoma
Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid
Status: Active, not recruiting Condition: Breast Cancer
PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer
Status: Active, not recruiting Condition: Prostate Cancer
Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy
Status: Completed Condition: Prostate Cancer
Re-treatment of Patients With Paget's Disease Using Zoledronic Acid
Status: Completed Condition: Paget's Disease of the Bone
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
Status: Completed Condition: Multiple Myeloma; Breast Cancer
The Use of Zoledronic Acid to Complex Regional Pain Syndrome
Status: Not yet recruiting Condition: Complex Regional Pain Syndromes
Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis
Status: Completed Condition: Osteoporosis
Zometa and Circulating Vascular Endothelial Growth Factor (VEGF) in Breast Cancer Patients With Bone Metastasis
Status: Completed Condition: Metastatic Breast Cancer; Bone Metastases
Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)
Status: Recruiting Condition: Mesothelioma
Courtesy of ClinicalTrials.org
See more clinical trials for this drug
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||Type||RLD||Patent No.||Product||Substance||Delist_Flag||Patent Expiration||Exclusivity Expiration|
|INJECTABLE; IV (INFUSION)||021817||Apr 16, 2007||RX||Yes||4,939,130*PED||Y||<disabled>||<disabled>|
|INJECTABLE; IV (INFUSION)||021817||Apr 16, 2007||RX||Yes||7,932,241*PED||Y||<disabled>||<disabled>|
|INJECTABLE; IV (INFUSION)||021817||Apr 16, 2007||RX||Yes||8,052,987||<disabled>||<disabled>|
|The preview shows a limited data set. Complete access is available with a Subscription|
Export unavailable in trial.
Subscribe for complete access.
|zoledronic acid||Injection||0.05 mg/mL, 100 mL vial||Reclast||8/29/2008|
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639